Medications

Novartis says EU approves expanded use of Glivec

Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer.

Oncology & Cancer

New at-risk group identified for gastrointestinal stromal tumors

Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach ...

Oncology & Cancer

Three 'targeted' cancer drugs raise risk of fatal side effects

Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that ...

Oncology & Cancer

Large-scale cancer gene profiling is feasible but faces barriers

Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer, and that some ...

page 1 from 4